- Home
- STEL vs KURA Comparison
STEL vs KURA Comparison
Compare STEL & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEL
- KURA
- Stock Information
- Founded
- STEL 2007
- KURA 2014
- Country
- STEL United States
- KURA United States
- Employees
- STEL N/A
- KURA N/A
- Industry
- STEL Major Banks
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STEL Finance
- KURA Health Care
- Exchange
- STEL Nasdaq
- KURA Nasdaq
- Market Cap
- STEL 1.4B
- KURA 1.3B
- IPO Year
- STEL N/A
- KURA N/A
- Fundamental
- Price
- STEL $29.96
- KURA $15.92
- Analyst Decision
- STEL Hold
- KURA Strong Buy
- Analyst Count
- STEL 3
- KURA 7
- Target Price
- STEL $28.33
- KURA $29.83
- AVG Volume (30 Days)
- STEL 191.3K
- KURA 821.5K
- Earning Date
- STEL 10-25-2024
- KURA 11-07-2024
- Dividend Yield
- STEL 1.74%
- KURA N/A
- EPS Growth
- STEL 10.73
- KURA N/A
- EPS
- STEL 2.19
- KURA N/A
- Revenue
- STEL $438,640,000.00
- KURA N/A
- Revenue This Year
- STEL N/A
- KURA N/A
- Revenue Next Year
- STEL $1.04
- KURA N/A
- P/E Ratio
- STEL $13.66
- KURA N/A
- Revenue Growth
- STEL 3.93
- KURA N/A
- 52 Week Low
- STEL $21.27
- KURA $9.06
- 52 Week High
- STEL $30.92
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- STEL 64.50
- KURA 34.68
- Support Level
- STEL $26.28
- KURA $16.55
- Resistance Level
- STEL $30.61
- KURA $19.73
- Average True Range (ATR)
- STEL 0.87
- KURA 0.98
- MACD
- STEL 0.18
- KURA -0.05
- Stochastic Oscillator
- STEL 79.31
- KURA 8.86
About STEL Stellar Bancorp Inc.
Stellar Bancorp Inc is a U.S. based bank holding company. It mainly focuses on providing commercial banking solutions to local small and mid-sized businesses and professionals. The services provided by the company include business and personal deposits account, personal and business lending, mobile and online banking, merchant banking, and others. The company more than 50 full service banking centers.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.